More on ARTL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.72 |
|
|||
| Open | $0.70 | ||||
| 52 Wk High | $6.22 | ||||
| 52 Wk Low | $2.74 | ||||
| Day High | $0.76 | ||||
| Day Low | $0.70 | ||||
| P/E | N/A | ||||
| EPS | $-0.21 | ||||
| Volume | 479,154 | ||||
- Artelo Biosciences gets U.S. patent allowance for ART27.13 drug
- Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
- Form SCHEDULE 13G/A ARTELO BIOSCIENCES, INC. Filed by: ARMISTICE CAPITAL, LLC
- Form SCHEDULE 13G/A ARTELO BIOSCIENCES, INC. Filed by: INTRACOASTAL CAPITAL, LLC
- Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
- Form 10-Q ARTELO BIOSCIENCES, INC. For: Jun 30
- Artelo enrolls first patient in Phase 2 glaucoma trial for ART27.13
- Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
- New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Compos
- Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: MATSUI CONNIE
Entities mentioned with ARTL
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- Show More...
